Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period [clinicaltrials_resource:f03a2f8152c48c6b0410df4aad9586f4]
Dexmedetomidine
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required RASS score will be assessed approximately 2 hourly during the treatment period and during the 48-hour follow-up period [clinicaltrials_resource:f03a2f8152c48c6b0410df4aad9586f4]
Dexmedetomidine
Bio2RDF identifier
f03a2f8152c48c6b0410df4aad9586f4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f03a2f8152c48c6b0410df4aad9586f4
measure [clinicaltrials_vocabulary:measure]
Depth of sedation using the RA ...... atment, if clinically required
time frame [clinicaltrials_vocabulary:time-frame]
RASS score will be assessed ap ...... g the 48-hour follow-up period
description
Dexmedetomidine
identifier
clinicaltrials_resource:f03a2f8152c48c6b0410df4aad9586f4
title
Depth of sedation using the RA ...... g the 48-hour follow-up period
@en
type
label
Depth of sedation using the RA ...... a2f8152c48c6b0410df4aad9586f4]
@en